Strategic Acquisition Cellix is now part of Randox Laboratories since 2023, presenting a sales opportunity to align microfluidic expertise with Randox diagnostic development and co-development projects.

Automated Manufacturing Leading a €3.3m DTIF project to create a fully automated, closed system for cell manufacturing in gene therapies suggests demand for robust microfluidic and automation solutions that we can support with scalable instruments.

Therapeutic Focus Active engagement in thrombosis, oncology, atherosclerosis, inflammation, infectious diseases, stem cell research, sickle cell disease, asthma and allergies indicates multiple high-value application areas for targeted instrumentation and microfluidic analyses.

Lab Maturation Aiming to democratize flow cytometry with user-friendly benchtop solutions signals opportunity to supply accessible analysis tools and complementary sorting/instrumentation to small labs and core facilities alike.

Collaborative Growth Existence of partnerships with European funding programs and research institutions suggests potential for co-development, pilot programs, and grant-enabled procurement of our technologies.